Dillan DiNardo (@DillanDiNardo) / X

Dillan DiNardo

503 posts

Dillan DiNardo

@DillanDiNardo

Scaling the substrate for programmable mental states @MindstateDesign | Digital neuropsychopharmacology + bioengineering | ex-biotech VC

San Francisco & Pittsburgh

Joined August 2013

Pinned
Dillan DiNardo
@DillanDiNardo
Sep 24, 2025
1/ It feels surreal to announce completion of the first human trial in the development of our neurotech platform for designing mental states, from the molecular level. Human experience is now programmable. A🧵on the sequel to psychedelics & the first new "emotion in a bottle."
365K
Dillan DiNardo
@DillanDiNardo
Sep 5, 2024
1/ We're thrilled to announce we've received both FDA & EMA approval to begin human trials in the development of our neurotech platform for designing altered states. It’s time to move beyond “psychedelics” and begin the precision design of mood, cognition, and perception. (1/9)
357K
Dillan DiNardo
@DillanDiNardo
Sep 5, 2024
Replying to @DillanDiNardo
3/ We were obsessed with the question of why different psychedelics change consciousness in different ways. DMT loads you into an alternative environment populated by entities. 5-MeO-DMT blasts you into a blissful formless void. Ibogaine transports you into a series of your life
18K
Dillan DiNardo
@DillanDiNardo
Sep 5, 2024
Replying to @DillanDiNardo
9/ We don’t need to eliminate the psychoactive effects of psychedelics. We need the ability to choose the effects that are helpful – to transform these largely effective but unpredictable messes of psychoactive effects into a series of precision-targeted psychoactive profiles. We
14K
Dillan DiNardo
@DillanDiNardo
Sep 5, 2024
Replying to @DillanDiNardo
4/ It seemed obvious that the experiential differences between psychedelics hold the keys to the biological basis of consciousness. If we could figure out which differences in psychedelic pharmacology drive which differences in consciousness, we’d understand the mechanisms of
15K
Dillan DiNardo
@DillanDiNardo
Oct 2, 2024
Fantastic piece on the future of psychedelics in @TIME from @Jamie_Ducharme. We don't have to accept the unpredictability of popular legacy psychedelics; we should work toward precision-designing modified conscious states.
Safer Psychedelic Drugs May Be Coming
From time.com
8.5K
Dillan DiNardo
@DillanDiNardo
Sep 5, 2024
Replying to @DillanDiNardo
Thanks to @DavidOvalle305 for the great coverage in @washingtonpost!
Analysis | FDA gives an early nod to psychedelic research
From washingtonpost.com
17K
Dillan DiNardo
@DillanDiNardo
Sep 5, 2024
Replying to @DillanDiNardo
5/ Our Osmanthus platform is driven by direct human experience. It represents the scaling, quantification, and systematization of the Shulgin tradition of direct experimentation. We’ve scaled with 70,000 human reports made possible by Shulgin’s chemistry and the psychonauts who
15K
Dillan DiNardo
@DillanDiNardo
Sep 5, 2024
Replying to @DillanDiNardo
7/ Our first line of psychotropic effects is built on the single base formula of the Shulgin psychedelic 5-MeO-MiPT, commonly called moxy – a “psychedelic tofu”. At normalized clinical doses there are some basic psychedelic effects but no mystical experiences or entities or
12K
Dillan DiNardo
@DillanDiNardo
Sep 5, 2024
Replying to @DillanDiNardo
6/ The psychedelics were the tools, not the end game. They were for psychiatry what the microscope was for biology and what the telescope was for astronomy. We’ve used the tools to map the biological basis of the varieties of psychedelic effects, and we’re now moving into human
12K
Dillan DiNardo
@DillanDiNardo
Sep 5, 2024
Replying to @DillanDiNardo
8/ We take a combination approach where we break apart the serotonergic action with 5-MeO-MiPT and recombine it, one by one, with a collection of other compounds that carry pharmacologies we’ve identified as modulating one or more of the 600+ psychedelic effects we’ve catalogued.
12K
Dillan DiNardo
@DillanDiNardo
Mar 8, 2024
Unsurprisingly, LSD receives Breakthrough Therapy designation. Phase 2b trial of low-dose 100 µg LSD for Generalized Anxiety Disorder shows 65% clinical response rate and 48% clinical remission. No additional therapeutic intervention beyond monitoring.
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability...
From ir.definiumtx.com
4.1K
Dillan DiNardo
@DillanDiNardo
Feb 10, 2022
1/ Today we’re unveiling Mindstate Design Labs: a biotech platform for the precision design of novel psychedelic states. @MindstateDesign
mindstate.design
Mindstate Design Labs
A psychedelic drug development company designing altered states of consciousness for mental health therapeutics.
Dillan DiNardo
@DillanDiNardo
Feb 15, 2023
Helpful snapshot of the psychedelics industry from @EmpathVentures
4.3K